Agoracom Blog Home

Posts Tagged ‘pharma’

VIDEO – Valeo Pharma (VPH: CSE) (VPHIF: OTCQB) Hits Record Annual Revenues Of $13.6 MILLION … Targeting $150 MILLION By 2025

Posted by AGORACOM-JC at 7:30 PM on Sunday, March 6th, 2022
Valeo pharma 300x300

Valeo Pharma is already a successful, revenue-generating, small-cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.    

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small-cap pharma companies.     

2021 HIGHLIGHTS:

  • $13.6 MILLION              Record Annual Revenues Up 81% Over 2020
  • $9.1 MILLION                Record 2nd Half Revenues
  • $4 MILLION                   Record Annual Gross Profit Up 186% over 2020
  • $43 MILLION                 Record Financing Through 2021 / Subsequent To Year End 

If you think these numbers are impressive, consider the fact that 3 important factors to their business were only partially launched in fiscal 2021, namely:

●       Each of their transformational products were staggered released, now fully released

●       Insurance & Government reimbursement approvals were staggered, now nearly 100%

●       Corporate Structuring related to staffing and distribution was ramping, now 100%

$150 MILLION REVENUE TARGET BY 2025

Despite the ramp up and staggered milestones, this translated into $9.1M in second half revenue for $VPH, which we would easily extrapolate at 150% – 200% for all of 2022 or ~ $23M – $27M in revenue … but that is just our own back of the napkin math with imperfect information.

If you want to hear it straight from the horses’ mouth $VPH believes it can achieve $150M in revenue by 2025.

Commenting on the fourth quarter and record year-end 2021 results, Luc Mainville , Senior Vice-President and Chief Financial Officer stated:

“As expected, the significant increase in Q4-2021 revenues and record annual revenues resulted mainly from the addition of the new products launched during the year. Valeo is now very well positioned to leverage its new corporate and commercial infrastructure to capitalize on the market potential of its existing product portfolio,”

 Sit back, relax and watch this powerful interview with CEO Steve Saviuk.

VIDEO – Valeo Pharma Immune Booster Now Available In ~300 Stores Under Loblaws Banner, Another Step Closer to 2025 Revenue Target of $160M

Posted by AGORACOM-JC at 1:40 PM on Thursday, January 6th, 2022
Valeo pharma 300x300

Valeo Pharma is already a successful, revenue-generating, small-cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.    

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small-cap pharma companies.     

The company released stellar a Q3 with the following highlights:    

  • Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.
  • Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.
  • Record 9 months revenues at $10.2 million , up 94%

But wait, there’s more…

The company announced that Hesperco™ Is Now Available At Loblaws, Hesperidin Covid-19 Clinical Trial Results Submitted For Publication.

  • Approved by Health Canada for immune support, is now available for sale in approximately 300 stores under the Loblaw’s banners including:
    • Loblaws
    • Dominion,
    • Zehrs,
    • Fortinio’s,
    • Your Independent Grocer and Superstore

Steve Saviuk , CEO commented,

We are very pleased to announce that Hesperco is now available in over 300 Loblaw banner stores. The immune support properties of hesperidin, the sole medicinal ingredient contained in Hesperco capsules, has been well documented in numerous scientific publications. We are also encouraged by the results of the Hesperidin Covid-19 clinical trial which has recently been submitted for publication. The study concluded that hesperidin could have beneficial effects and may help reduce certain Covid-19 symptoms. The publication further suggested that earlier treatment of longer duration and/or higher dosage should be studied.”

But wait, there’s more…

The company Closed Previously Announced Upsized $15 Million Bought Deal Private Placement And Concurrent $10 Million Private Placement with Investissement Québec.

Now sit back, relax and watch this powerful interview with Valeo Pharma.

Valeo Pharma $VPH $VPHIF Announces $4.0 Million Non-Brokered Private Placement of Non-Convertible Debentures $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 8:44 AM on Wednesday, April 14th, 2021
  • Announced today a non-brokered private placement of up to 4,000 unsecured non-convertible debentures units (the “Debenture Units”) at a price of $1,000 per Debenture Unit for maximum gross proceeds of $4,000,000
  • Valeo insiders participate for $2.6 million

MONTREAL , April 14, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today a non-brokered private placement of up to 4,000 unsecured non-convertible debentures units (the “Debenture Units”) at a price of $1,000 per Debenture Unit for maximum gross proceeds of $4,000,000 (the “Offering”).

Each Debenture Unit will consist of one (1) unsecured non-convertible debenture of the Company in the principal amount of $1,000 (each, a “Debenture”) and 200 Class “A” share purchase warrants (each, a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Class “A” Share of the Company (each, a “Share”) at an exercise price of $1.60 at any time up to 24 months following the closing date of the Offering (the “Closing Date”). The Debentures will mature at the latest 9 months after the closing and will bear interest at a rate of 8% per annum from the date of issue, payable in cash, semi-annually in arrears.

“We are appreciative of the continued support from insiders and investors close to the Company  in this placement”, said Steve Saviuk , Valeo’s Chief Executive Officer. “This financing will strengthen our balance sheet at a time of three important product launches for Valeo, Enerzair® Breezhaler®, Atectura® Breezhaler® and Redesca™. Commercialized through two distinct sales forces, these products are key drivers to our growth over the coming years”.

The net proceeds of the Offering will be used for working capital and general corporate purposes.

Closing of the Private Placement is expected to occur on or about April 23, 2021 and is subject to regulatory approval including that of the CSE. The Company may pay finder’s fees on the non-insider portion of the Private Placement, in compliance with applicable securities laws. All securities issued in connection with the Private Placement will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation.

The issuance of Convertible Debentures to the insiders will be considered related party transactions within the meaning of Multilateral Instrument 61-101 (“MI 61-101”). The Company intends to rely on the exemptions from the requirements of MI 61-101 in respect of any Insider Participation.

This press release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.

About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurology, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter .

Forward Looking Statements

This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. 

Valeo Pharma $VPH $VPHIF Completes Negotiations with Pan-Canadian Pharmaceutical Alliance for Redesca® and Redesca HP® $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 8:12 AM on Tuesday, April 6th, 2021
  • Completed its negotiations and entered into a letter of intent (“LOI”) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding Redesca® and Redesca HP®, its low molecular weight heparin (“LMWH”) biosimilar, for the prevention and treatment of thromboembolic disorders.

MONTREAL , April 6, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian specialty pharmaceutical company, today announced that it has completed its negotiations and entered into a letter of intent (“LOI”) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding Redesca® and Redesca HP®, its low molecular weight heparin (“LMWH”) biosimilar, for the prevention and treatment of thromboembolic disorders.

“The successful conclusion of negotiations with pCPA is a significant milestone delivered for the Redesca® commercialization program. We can now exchange with the provincial, territories and federal instances to ensure coverage under publicly funded drug plans in Canada “, said Steve Saviuk , Valeo’s CEO.” While most prescriptions of LMWHs are initiated in the hospital, retail pharmacies play an important role in providing continued treatment to patients when they are discharged from hospital. Coverage by publicly funded drug plans are therefor a key component in making treatment available to Canadians”.

Commenting on the pCPA LOI, Frederic Fasano , Valeo’s President and Chief Operating Officer said; “We are particularly pleased to make Redesca ® available soon for Canadian patients and also for hospitals. The team at Valeo have worked tirelessly to ensure a robust supply of Redesca ® especially in the current pandemic conditions where patients suffering from SARS-CoV-2 are undergoing severe coagulopathy with various thromboembolic complications. LMWHs, like Redesca ® are key to prevent and treat those severe COVID-19 related thrombotic events.”

Established in August 2010 , the pan-Canadian Pharmaceutical Alliance (pCPA) conducts joint provincial/territorial/federal negotiations for brand name and generic drugs in Canada to achieve greater value for publicly funded drug programs and patients through the use of the combined negotiating power of participating jurisdictions.

About Redesca®, Redesca HP®

Redesca® is a low molecular weight heparin biosimilar. LMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism. Redesca® has more than 8 years of proven in-market safety internationally and more than 150 million patient days treated in Europe alone.

About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter .

Read More: https://agoracom.com/ir/ValeoPharma/forums/discussion/topics/758564-valeo-pharma-completes-negotiations-with-pan-canadian-pharmaceutical-alliance-for-redesca-and-redesca-hp/messages/2310948#message

AGORACOM Small Cap 60: What Gives Valeo Pharma A Competitive Advantage In The $700M CAD / Year Asthma Market? $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 12:02 PM on Thursday, April 1st, 2021

Valeo Pharma $VPH $VPHIF Reports its First Quarter 2021 Results and Highlights $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 6:40 PM on Wednesday, March 31st, 2021
  • Valeo secured the Canadian rights to Enerzair® Breezhaler® and Atectura® Breezhaler®, two new innovative Asthma therapies
  • Q1-21 net revenues of $1.9 million , up 11 % vs Q1-20
  • Frederic Fasano appointed as President and Chief Operating Officer
  • Redesca® and Redesca HP® receive Health Canada approval, launching in Q3
  • Hesperco™ capsules at the core of a Montreal Heart Institute’s COVID-19 study

MONTREAL , March 31, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, today reported its financial results for the first quarter ended January 31, 2021 .

“Our first quarter has laid the foundation for a transformational year for Valeo. The commercialization agreement with Novartis Canada positions  Valeo as one of the leading Canadian companies in respirology .  We are excited about the opportunity to enter the growing asthma market with two innovative drugs, Enerzair® Breezhaler® and Atectura® Breezhaler®.  The Canadian asthma market exceeds $700 million annually 1 and is expected to growth at 2-3% per year over the next ten years. We expect combined peak sales of these two new drugs to exceed $100 million annually.”, said Steve Saviuk , Valeo’s CEO. “With the coming launch of Redesca, our low-molecular-weight-heparin biosimilar, and the Montreal Institute of Cardiology’s ongoing Covid-19 clinical trial involving Hesperco capsules, 2021 marks a turning point in Valeo’s history”.

Commenting on the first quarter 2021 results, Luc Mainville , Senior Vice-President and Chief Financial Officer said, “Our net revenues for the quarter continued to grow and reflected the addition of several products during the latter part of our 2020 fiscal year. Our first quarter results were impacted by calendar year-end slowdown of the pharma sector as well as increase in operating expenses to support our growth initiatives. Sales & Marketing expenses increased due to the addition of Redesca’s national key account manager team. Our General & Administrative expenses also increased during the quarter as a result of the addition to the Head Office personnel and increased marketing related expenses. We expect additional investments to be made in 2021 as we prepare ourselves to support the Canadian commercialization of Enerzair® Breezhaler® and Atectura® Breezhaler® already approved by Health Canada and available for sale. We anticipate strong revenue growth in the second quarter of fiscal 2021 and accelerated growth in the coming quarters as a result of these product additions which will derive incremental margins and drive our profitability going forward.

References:

  1. IQVIA CDH June 2020

First Quarter 2021 Financial Results and Highlights

  • Net revenues were $1.9 million for the quarter ended January 31, 2021 compared to $1.7 million for the quarter ended January 31, 2020 . The increase over the previous comparable period is mainly due to the Onstryv revenue growth and the launch of new products such as Ametop, Yondelis and the launch of Sodium Ethacrynate in the U.S. ;
  • Net loss of $1.7 million for the quarter ended January 31, 2021 compared to $1.1 million for the quarter ended January 31, 2020 . The increase in net loss is a result of the increase in Sales & Marketing and General & Administrative expenses required to position Valeo for solid revenue growth in 2021; and
  • Adjusted EBITDA loss of $1.1 million for the quarter ended January 31, 2021 compared to $0.9 million for the quarter ended January 31, 2020 .

First Quarter 2021 Business and Product Highlights

  • In January 2021 , the Company received notice of a positive recommendation by Quebec’s Institut national d’excellence en santé et en services sociaux (“INESSS”) to the Health Minister for the inclusion of Redesca® and Redesca® HP, on the list of medications covered by the Régie de l’assurance maladie du Québec (RAMQ);
  • In January 2021 , the Company appointed Mr. Frederic Fasano to the newly created position of President and Chief Operating Officer. Mr. Fasano is a seasoned Canadian and international pharma executive having lead pharmaceutical organizations in Europe and Canada. His addition augments Valeo’s senior leadership team and support expansion of Valeo’s commercial activities;
  • In December 2020 , the Company announced that its shares were eligible for electronic clearing and settlement in the U.S. through the Depository Trust Company (“DTC”);
  • In December 2020 , the Company received a Notice of Compliance from Health Canada for its Redesca and Redesca HP low molecular weight heparin (“LMWH”) biosimilars; and
  • In November 2020 , the Company received a Notice of Compliance from Health Canada granting market authorization for Amikacin and commenced shipments of Ethacrynate Sodium in the U.S. market.

Subsequent Events

  • In March 2021 , the Company entered into a Commercial and Supply Agreement with Novartis Pharmaceuticals Canada Inc. for the Canadian commercialization by Valeo of two innovative asthma therapies, Enerzair ® Breezhaler ® (indacaterol (as acetate), glycopyrronium (as bromide) and mometasone furoate) and Atectura ® Breezhaler ® (indacaterol (as acetate) and mometasone furoate); and
  • In February 2021 , the Company announced that Hesperco™ capsules, approved by Health Canada for immune support, will be at the core of the Montreal Heart Institute’s (“MHI”) clinical trial, “The Hesperidin Coronavirus Study”;

Q1 2021 Webcast and Conference Call

Valeo will host a conference call to discuss the first quarter 2021 results and highlights on Thursday April 1, 2021 at 8.30am (EST) . The telephone numbers to access the conference call are 1-888-231-8191 and 647-427-7450. An audio replay of the call will be available. The numbers to access the audio replay are 1-855-859-2056 and 416-849-0833 using the following access code (5555964).

A live audio webcast of the conference call will be available via:

https://produceredition.webcasts.com/starthere.jsp?ei=1444812&tp_key=929d96e070

Financial Statements and MD&A

Valeo Pharma’s financial statements and Management’s Discussion and Analysis for the three-month ended January 31, 2021 are available on SEDAR at www.sedar.com

About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter .

Forward Looking Statements

This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

AGORACOM Small Cap 60: How Big Is Valeo Pharma’s $VPH $VPHIF Commercialization and Supply Agreement With Novartis? $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 12:04 PM on Wednesday, March 31st, 2021
Valeo Pharma (@valeo_pharma) | Twitter

VIDEO – Valeo Pharma $VPH $VPHIF Enters Commercialization and Supply Agreement With Novartis To Address the $700M/ Year CDN Asthma Medication Market $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 5:41 PM on Monday, March 29th, 2021

Valeo Pharma Inc . (VPH: CSE) (VPHIF: OTCQB) (VP2: FSE) announced today that it has entered into a Commercialization and Supply Agreement with Novartis Pharmaceuticals Canada Inc.for the Canadian commercialization by Valeo of two asthma therapies, Enerzair ® Breezhaler ® (indacaterol (as acetate),  glycopyrronium (as bromide) and mometasone furoate) 3 and Atectura ® Breezhaler ® (indacaterol (as acetate) and mometasone furoate).

Under the Agreement, Valeo will be responsible for medical and commercial activities for an initial 8 year period.

How Significant Is This Market?

At present, almost 4 million Canadians are living with asthma a serious health issue affecting all age groups. Patients with severe asthma live in fear of potential exacerbations which remain highly prevalent even with today’s most advanced therapies. The Canadian market for asthma medication exceeds $700M annually.

What Does The CEO of Valeo say about the deal?

“We are extremely pleased to be partnering with Novartis to launch these two  asthma drugs in the coming weeks. Commercializing Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® will immediately position Valeo as one of the leading Canadian respiratory companies providing first in-class and best in-class asthma therapies. The Canadian asthma maintenance market exceeds $700M annually,” said Steve Saviuk , CEO of Valeo. “This partnership is perfectly aligned with Valeo’s vision and mission of building a Canadian anchor pharmaceutical company by driving therapeutic innovation to patients in need. We look forward to building a long and mutually beneficial relationship with Novartis that will help both companies fulfill their respective missions.”

Sit Back, relax and watch this powerful interview with Steve Saviuk , CEO of Valeo.

Valeo Pharma $VPH $VPHIF Enters into an Agreement for Enerzair® Breezhaler® and Atectura® Breezhaler® in Canada $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 10:47 AM on Monday, March 29th, 2021
Valeo Pharma (@valeo_pharma) | Twitter
  • Valeo to commercialize Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® , 2 innovative asthma therapies approved by Health Canada
  • Positions Valeo as one of the leading Canadian Respiratory companies
  • Almost 4 million Canadians afflicted with asthma 1 ; Canadian market for asthma medication exceeds $700M annually 2

MONTREAL , March 29, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, announced today that it has entered into a Commercialization and Supply Agreement (the ” Agreement “) with Novartis Pharmaceuticals Canada Inc. (” Novartis “) for the Canadian commercialization by Valeo of two asthma therapies, Enerzair ® Breezhaler ® (indacaterol (as acetate),  glycopyrronium (as bromide) and mometasone furoate) 3 and Atectura ® Breezhaler ® (indacaterol (as acetate) and mometasone furoate) 4 .

Under the Agreement, Valeo will be responsible for medical and commercial activities for Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® for an initial 8 year period.

At present, almost 4 million Canadians are living with asthma 1 , a serious health issue affecting all age groups. Patients with severe asthma live in fear of potential exacerbations which remain highly prevalent even with today’s most advanced therapies . Asthma related exacerbations are concerning because of their associated mortality burden and also because of the increased risk of side effects from the use of systemic corticosteroids. Furthermore, there is growing evidence highlighting the lack of symptom control currently achieved in asthma. 39% 5 of patients remain uncontrolled, despite available dual LABA/ICS medications, primarily due to low adherence, treatment misuse and poor inhaler technique. There is an urgent need to add effective maintenance treatment options to  more efficiently address  symptoms as well as asthma related long-term complications and mortality.

“We are extremely pleased to be partnering with Novartis to launch these two  asthma drugs in the coming weeks. Commercializing Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® will immediately position Valeo as one of the leading Canadian respiratory companies providing first in-class and best in-class asthma therapies. The Canadian asthma maintenance market exceeds $700M annually,” said Steve Saviuk , CEO of Valeo. “This partnership is perfectly aligned with Valeo’s vision and mission of building a Canadian anchor pharmaceutical company by driving therapeutic innovation to patients in need. We look forward to building a long and mutually beneficial relationship with Novartis that will help both companies fulfill their respective missions.”

“This agreement with Valeo Pharma  fits with  our overall strategy to provide innovative medicines that have the potential to improve health outcomes,” said Andrea Marazzi , Head, Country Pharma Organization, Novartis Pharmaceuticals Canada Inc. “Valeo’s commitment and focus to bring Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® to Canadians, combined with our strong respiratory experience, brings  a solution that will help make asthma control a more attainable goal for some Canadians.”

Commenting on this commercial agreement with Novartis, Frederic Fasano , Valeo’s recently appointed President and COO said, “Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® are both benefitting from an extensive phase III clinical trial program including more than 7,500 asthma patients. The efficacy of both treatments on symptoms, lung function and rate of exacerbations have been demonstrated and this will provide Canadian patients with a significant improvement over current standards of care.” He added, “This significant addition to our expanding product portfolio is key to achieving our growth objectives. It will provide the basis for the upscaling of our organization and set the stage for future international expansion.”

The Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® will both be available in the hydrofluoroalkane/chlorofluorocarbon (HFA/CFC)-free Breezhaler ® device.

Atectura, Enerzair and Breezhaler are registered trademarks.

Source: https://agoracom.com/ir/ValeoPharma/forums/discussion/topics/758170-valeo-pharma-inc-enters-into-an-agreement-for-enerzair-breezhaler-and-atectura-breezhaler-in-canada/messages/2310143#message

Valeo Pharma $VPH $VPHIF to Report First Quarter 2021 Results and Hold Investors Conference Call / Webcast $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 2:41 PM on Friday, March 26th, 2021
Valeo Pharma (@valeo_pharma) | Twitter
  • Financial results and highlights for the first quarter ended January 31, 2021 on Wednesday March 31, 2021 after market close.
  • Valeo will host a conference call to discuss those results and highlights on Thursday April 1, 2021 at 8.30am (ET) .

MONTREAL , March 26, 2021  – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the first quarter ended January 31, 2021 on Wednesday March 31, 2021 after market close.

Valeo will host a conference call to discuss those results and highlights on Thursday April 1, 2021 at 8.30am (ET) . The telephone numbers to access the conference call are 1-888-231-8191 and 647-427-7450. An audio replay of the call will be available. The numbers to access the audio replay are 1-855-859-2056 and 416-849-0833 using the following access code (5555964).

A live audio webcast of the conference call will be available via: https://produceredition.webcasts.com/starthere.jsp?ei=1444812&tp_key=929d96e070

About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter .